Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety

YU-YUN SHAOFeng Y.-H.Yen C.-J.Yang T.-S.YING-CHUN SHENChao Y.Chen J.-S.Su C.-Y.Chen W.-J.Hsiang H.-L.CHIH-HUNG HSU2022-10-252022-10-2520220929-6646https://www.scopus.com/inward/record.uri?eid=2-s2.0-85139275802&doi=10.1016%2fj.jfma.2022.09.005&partnerID=40&md5=cd2fcca8c8c508bdde9b57af614bb72fhttps://scholars.lib.ntu.edu.tw/handle/123456789/623995[SDGs]SDG3Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safetyjournal article10.1016/j.jfma.2022.09.005361532102-s2.0-85139275802